Navigation Links
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel

22 US Oncology Affiliated Physicians Participate in ASCO Proceedings

HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancer researcher affiliated with the US Oncology Research Network presented findings from a randomized, multicenter phase III trial that compared the disease-free survival (DFS) obtained with two regimens of adjuvant therapy for patients with high-risk breast cancer.

The study results were given in an oral presentation by Dr. David Loesch of Central Indiana Cancer Centers, at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 2-5, 2007 in Chicago. Dr. Loesch is the lead investigator and a member of US Oncology's breast cancer research committee.

The study, titled "A randomized, multicenter phase III trial comparing doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for high risk breast cancer" (abstract number 517) was conducted among women with local, operable, confirmed stage I-III adenocarcinoma, who had primary surgery, with no residual tumor.

The research found that Therapy Arm 2 (ATT) (doxorubicin 50 mg/m2 plus paclitaxel 200 mg/m2 repeated every three weeks for four cyclespaclitaxel 80 mg/m2 weekly x12) AT+WP can be considered equal to ACT as a standard treatment in the community. It has more peripheral neuropathy than ACT; but the neuropathy is reversible. In a repeat analysis of the triple negative subgroup, APWP was superior to ACT in overall survival (OS).

In addition, 22 physicians and researchers affiliated with US Oncology participated in oral and poster presentations, moderated panels and published studies at this year's ASCO conference in Chicago. The researchers presented findings on a variety of disease states including lung, gastrointestinal, genitourinary, gynecologic, breast and melanoma.

    -- Daniel Von Hoff, M.D.
, Chief Scientific Officer:  The Complete Phase lb

       Clinical Trial: A Method to Accelerate New Agent Development


    -- Michael Teneriello, M.D., Co-Chair, Gynecologic Cancer Research

       Committee, US Oncology Research:  Results of a Phase II evaluation of

       nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum-

       sensitive patients with recurrent ovarian, peritoneal, or fallopian

       tube cancer


    -- Patrick Timmins, III, M.D.:  Preliminary results of an open-label study

       to evaluate the efficacy and tolerability of aprepitant for the

       prevention of chemotherapy-induced nausea and vomiting associated with

       carboplatin-containing chemotherapy regimen in patients with ovarian

       cancer, primary peritoneal or fallopian tube carcinoma (stage I-IV) or

       papillary serous cancer of the uterus


    -- Craig Reynolds, M.D., Co-Chair Lung Cancer Research Committee:  An

       open-label, Phase II trial of nanoparticle albumin bound paclitaxel

       (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients

       with advanced non-squamous Non-Small Cell-Lung Cancer (NSCLC)


    -- Thomas Cartwright, M.D., Co-Chair, GI Cancer Research Committee:

       Results of a Phase II trial of cetuximab+XELIRI as first-line therapy

       of patients with advanced and/or metastatic colorectal cancer


    -- Craig Reynolds, M.D.:  A randomized phase 3 trial of gemcitabine with

       or without carboplatin in performance status 2 (PS2) patients (pts)

       with advanced (stage IIIB with pleural effusion or IV) Non-Small-Cell

       Lung Cancer (NSCLC)


    -- Robert Raju, M.D.:  Pemetrexed (P) in relapsed Small-Cell Lung Cancer

       (SCLC): Preliminary results of a Phase II trial


    -- Don Richards, M.D., Ph.D.:  The impact of shortened vitamin

       supplementation lead-in time before pemetrexed (P) in patients with

       relapsed Small-Cell Lung Cancer (SCLC)


    -- J.R.
 Hoverman, M.D., Medical Director of Managed Care, US Oncology:

       Assessment of medication safety in the outpatient setting


    -- Manuel Modiano, M.D.:  A phase I study of TPI 287, a third generation

       taxane, administered every 21 days in patients with advanced cancer


    -- Joanne Blum, M.D., Ph.D.:  Phase II study of eribulin mesylate (E7389)

       halichondrin b analog in patients with refractory breast cancer


    -- Alexander Spira, M.D.:  Phase II study of eribulin mesylate (E7389), a

       mechanistically novel inhibitor of microtubule dynamics, in patients

       with advanced Non-Small Cell-Lung Cancer (NSCLC)


    -- John Pippen, Jr., M.D., F.A.C.P.:  "A Historical Overview of the

       Treatment of Prostate Cancer and the Evolution of Bone Marrow

       Transplantation"


    -- Marcus Neubauer, M.D., Co-Chair:  Lung Cancer Research Committee: A

       clinical pathways project to promote evidence-based medicine in a large

       community oncology practice


    -- Domingo Perez, M.D.:  Phase II trial of carboplatin, weekly paclitaxel

       and biweekly bevacizumab in patients with unresectable stage IV

       melanoma


    -- Nicholas Robert, M.D., Co-Chair Breast Cancer Research Committee: BCIRG

       006: Docetaxel and trastuzumab-based regimens improve DFS and OS over

       AC-T in node positive and high risk node negative HER2 positive early

       breast cancer patients: Quality of Life (QOL) at 36 months follow-up


    -- Dr. Alexander Spira:  Perifosine (P) an active agent in the treatment

       of patients with advanced sarcoma


    -- Dr. Alexander Spira:  iTARGET: A Phase II Trial to Assess the Response

       to Gefitinib in Epidermal Growth Factor Receptor (EGFR)-Mutated

       Non-Small Cell-Lung Cancer (NSCLC) Tumors


    -- Dr. Hakan Kaya:  Survival outcomes for multiple myeloma over three

       decades: A Surveillance, Epidemiology, and End Results (SEER) analysis


    -- Dr. Hakan Kaya:  
Survival and secondary malignancy rates for adjuvant

       radiation therapy versus observation in stage I testicular seminoma: A

       Surveillance, Epidemiology, and End Results (SEER) analysis


    -- Dr. Kelly Pendergrass:  The Advanced Renal Cell Carcinoma Sorafenib

       (ARCCS) expanded access trial: safety and efficacy in patients (pts)

       with Non-Clear Cell (NCC) Renal Cell Carcinoma (RCC)


    -- Roger Lyons, M.D.:  Tolerability and hematologic improvement assessed

       using three alternative dosing schedules of azacitidine in patients

       with myelodysplastic syndromes


    -- Thomas Hutson, D.O., PharmD, Associate Chair, GU Cancer, US Oncology

       Research:  Pazopanib (PAZ, GW786034) in pts w/ metastatic Renal Cell

       Carcinoma (RCC): Interim results of a PH II Randomized Discontinuation

       Trial (RDT)


    -- Guru Sonpavde, M.D.:  Sunitinib malate is active and synergistic with

       cisplatin against human urothelial carcinoma in a preclinical model


About US Oncology Research

The US Oncology Research Network is an established community-based research operation specializing in all phases of cancer clinical trials. The research network currently has 528 physicians actively enrolling patients, 82 research sites, and is currently involved in 65 open research trials. The network has contributed to the development of 24 of 30 of the latest cancer- fighting drugs approved by the Food and Drug Administration for use. Since 1993, more than 32,000 patients have participated in clinical trials managed by US Oncology network practices. For more information, visit the "Research" section under "Our Services" on the company's Web site, http://www.usoncology.com.

About US Oncology, Inc.

US Oncology, headquartered in Houston, is one of the nation's largest cancer treatment and research networks. US Oncology provides extensive services and s upport to its affiliated cancer care sites nationwide to help them expand their offering of the most advanced treatments and technologies, build integrated community-based cancer care centers, improve their therapeutic drug management programs, and participate in many of the new cancer-related clinical research studies. US Oncology also provides a broad range of services to pharmaceutical manufacturers, including product distribution and informational services such as data reporting and analysis.

According to the company's last quarterly earnings report, US Oncology is affiliated with 1077 physicians operating in 433 locations, including 90 radiation oncology facilities in 38 states.

CONTACT: Kimberly Rutherford of US Oncology, +1-832-601-6193,, or Elizabeth Vocke for US Oncology,+1-813-775-6202, Kimberly.Rutherford@usoncology.com Elizabeth.Vocke@hillandknowlton.com

Web site: http://www.usoncology.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... , Feb. 17, 2017   ... to protecting the rights of victims injured by ... prompted regulators to call for better reporting. Congress ... Safety concerns involving power morcellators and ... (FDA) to investigate how hospitals report injuries and ...
(Date:2/17/2017)... According to a new market research report ... Application (Cleanroom Monitoring, Contamination Monitoring of Liquids), and End User (Healthcare ... the market is expected to reach USD 330.6 Million by 2021 ... from 2016 to 2021. Continue Reading ... ...
(Date:2/17/2017)... 17, 2017 Research and Markets has announced the ... report to their offering. ... report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and Rest ... through 2022. Also, a six-year historic analysis is provided for these markets. ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... ... sustainable systems change designed to further positively impact the health and wellness of ... has long considered it our duty to seriously consider releasing our assets beyond ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. ... distinguish between corrective action (CA) and preventive action (PA)? , The methods share ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... operations executives and focusing on all facets of clinical trial planning and management. ... , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason Pasquin Agency, ... and business owners in and around the Hampton Roads metropolitan region, is joining ... forms of domestic violence. , There are multiple categories of domestic violence – ...
(Date:2/16/2017)... AL (PRWEB) , ... February 17, 2017 , ... ... protection assistance and financial planning services to families and entrepreneurs in the Birmingham ... a local adoptive mother who needs assistance with her medically challenged son, Anius. ...
Breaking Medicine News(10 mins):